Patented biomarker for cardiac injury. 

Cardiac myosin-binding protein C as a biomarker of acute myocardial infarction

cMyC has been measured in a variety of patient groups and directly compared to cardiac troponin T (cTnT) and cardiac troponin I (cTnI) measured in the same blood samples using high-sensitivity assays.
Direct comparisons of cMyC with cTnI/T have established the following:
  1. cMyC is more abundant than cTnT/I and consequently it is possible to measure smaller volumes of myocardium undergoing injury, based on spiking human heart into human blood.
  2. After myocardial injury cMyC can be detected in the blood earlier, and its concentration rises more rapidly, than cTnT/I or novel RNA biomarkers.
  3. Based on blood samples taken at presentation in patients with a suspected acute coronary syndrome, the diagnostic accuracy for acute myocardial infarction of cMyC, cTnI, and cTnT are similar, but cMyC is more efficient at rapid rule out.
  4. Despite cMyC having a sarcomeric location and kinetic profile that differs from cTnT/I, its concentration is similarly increased by chronic myocardial injury and acute (non-ischaemic) myocardial injury.
cMyC (Cardiac Myosin-binding protein C)
cMyC (Cardiac Myosin-binding protein C)